Plenary Session 3106

Controversies in Movement Disorders

Sunday, February 15, 2026
10:15 - 12:00 | Houston Ballroom

In this session, the faculty will discuss and explore hot and controversial topics from different angles based on scientific evidence that supports the pros and cons of each perspective.

Chairs:

Francisco Cardoso, Brazil
Connie Marras, Canada

Presenters:

Are We on the Verge of Identifying Disease-Modifying Therapies for Monogenic Parkinson’s Disease? [YES]

Are We on the Verge of Identifying Disease-Modifying Therapies for Monogenic Parkinson’s Disease? [NO]
Artur Schuh, Brazil

Is Artificial Intelligence Relevant for the Diagnosis of Parkinson’s Disease? [NO]
Mandar Jog, Canada

Is Artificial Intelligence Relevant for the Diagnosis of Parkinson’s Disease? [YES]
Joaquin Vizcarra, USA

Are Misfolded or Aggregated Protein Therapies Heroes or Villains? [Heroes]
Emilia Gatto, Argentina

Are Misfolded or Aggregated Protein Therapies Heroes or Villains? [Villains]
Gabor Kovacs, Canada

CSPC Liaisons:

Connie Marras, Canada
Emilia Gatto, Argentina

Learning Objectives

At the conclusion of this session, participants should be better able to:

1. Discuss the recent advances and new challenges for developing disease-modifying therapies for monogenic Parkinson's disease.
2. Measure the role of Artificial Intelligence (AI) in the daily practice and development of the field of Movement Disorders.
3. Discuss the potential positive and negative effects of reducing protein aggregation on neurodegenerative disease progression.

Recommended Audience

Clinician / General Neurology
Fellow / Resident / Student
Health Professional (non-physician)
Researcher / Basic Science

Education Level

Beginner / Foundational
Experienced
Expert